RÉSUMÉ
Chrysolina aeruginosa is a major pest of Artemisia ordosica, and knowledge of the spatial distribution pattern of its larvae in their natural habitat is crucial for the implementation of effective control measures. This study employed geostatistical methods to investigate the damage caused by larvae of different age groups and their spatial distribution pattern. The distribution of C. aeruginosa larvae, which cause damage to A. ordosica, differed significantly according to their age. Younger larvae were predominantly found in the middle and upper parts of the plant, whereas older larvae were mainly distributed in the middle and lower parts, with significant differences in distribution location. A generalized linear model analysis revealed that the height of the plant, and plant morphological characteristics such as height, crown width, and ground diameter were significantly correlated with the number of larvae present. Furthermore, the interaction of age with other variables had an impact on the number of larvae. Kriging interpolation showed that C. aeruginosa larvae were distributed in aggregated patches with strong spatial heterogeneity. The younger larvae were more abundant in the center of the sample site, while the older larvae tended to be distributed toward the edges. These findings provide valuable information for designing effective control programs.
RÉSUMÉ
Transmembrane TNF-α (tmTNF), a transmembrane form of TNF-α, was reported overexpressed in approximately 84% of triple-negative breast cancer (TNBC) patients and has emerged as a valid candidate biomarker for targeting TNBC. Paclitaxel is a first-line chemotherapeutic agent for the treatment of triple-negative breast cancer, but suffers from low water solubility, resulting in its low bioavailability. To achieve site-specific delivery of the anticancer chemotherapeutic drug (paclitaxel) on TNBC, we developed tmTNF-α monoclonal antibody (mAb)-conjugated paclitaxel (PTX) nanoparticles (NPs) (tmTNF-α mAb-PTX NPs) as potential nanocarriers. This targeted delivery-therapy nanocarriers was conducted by using an emulsification-evaporation method. tmTNF-α mAb-PTX NPs displayed favorable physicochemical properties. Compared with the control groups, tumor growth in human MDA-MB-231 xenograft mice was suppressed significantly by tmTNF-α mAb-PTX NPs. TmTNF-α mAb-PTX NPs exerts anti-tumor effects via promoting apoptosis and regulating mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) / protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) cascade, as well as AMP-activated protein kinase (AMPK) and nuclear factor Kappa-B (NF-κB) pathways. Moreover, tmTNF-α mAb-PTX NPs can inhibit the process of epithelial-mesenchymal transition (EMT) in TNBC to suppress tumor progression and metastasis. Together, the novel tmTNF-α mAb-PTX NPs based targeted drug delivery system is a potentially highly effective approach for treating TNBC.
Sujet(s)
Antinéoplasiques , Nanoparticules , Tumeurs du sein triple-négatives , Animaux , Anticorps monoclonaux , Antinéoplasiques/pharmacologie , Lignée cellulaire tumorale , Humains , Mammifères , Souris , Nanoparticules/composition chimique , Paclitaxel , Phosphatidylinositol 3-kinases , Tumeurs du sein triple-négatives/traitement médicamenteux , Tumeurs du sein triple-négatives/anatomopathologie , Facteur de nécrose tumorale alphaRÉSUMÉ
BACKGROUND: S100A8 plays a key role in many cellular processes and is highly expressed in various solid cancers. However, the prognostic role of S100A8 has not been well defined. Therefore, we conducted a quantitative meta-analysis to investigate whether or not S100A8 could be used as a prognostic biomarker in solid tumors. METHODS: PubMed, Web of Science, Embase, and Cochrane library were searched to acquire relevant studies that evaluated the association between expression of S100A8 and prognosis of cancer patients. Pooled hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs) were extracted to evaluate the association between S100A8 overexpression and Overall Survival (OS), Disease-Free Survival (DFS), Recurrence-Free Survival (RFS), and Progression-Free Survival (PFS). The expression of S100A8 was also validated by Flow cytometry, immunohistochemistry (IHC), and western blot. RESULTS: A total of 2,817 patients from 13 independent studies, ranging from 43 to 1,117 patients in size, were statistically analyzed. Our results indicated that a high level of S100A8 expression was significantly associated with poor OS, poor DFS, and poor PFS/RFS. In term of clinical pathological characteristics, a high expression level of S100A8 was significantly associated with differentiation grades, lymphatic metastasis, ER statue, and PR statue. The validation studies showed that the expression of S100A8 was at high levels in MDA-MB-231 (79.7%), MDA-MB-453 (89.2%), HTB-9 (70.2%), and T24 (53.3%) cells and it was higher in breast cancer tissue and bladder cancer tissue than their corresponding para-carcinoma tissue. CONCLUSIONS: S100A8 overexpression was significantly associated with poor clinical prognosis in cancer patients. S100A8 is potential a prognostic biomarker in breast cancer and bladder cancer. More well-designed studies with adequate prognostic data are needed to confirm the prognostic role of S100A8 revealed in this study.